Alnylam Pharmaceuticals(US:ALNY) ZACKS·2026-02-12 16:01Core Insights - Alnylam Pharmaceuticals reported $1.1 billion in revenue for Q4 2025, marking an 84.9% year-over-year increase, with an EPS of $1.25 compared to $0.06 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $1.14 billion by 3.35%, while the EPS exceeded the consensus estimate of $1.16 by 8.16% [1] Financial Performance Metrics - Net Product Revenue for Onpattro in the U.S. was $12.02 million, significantly below the estimated $5.37 million, reflecting a year-over-year decline of 39.7% [4] - Net Product Revenue for Oxlumo in the U.S. was $17.61 million, lower than the estimated $23.94 million, showing a 6.1% decrease year-over-year [4] - Net Product Revenue for Givlaari in the U.S. reached $56.34 million, surpassing the estimated $47.24 million, with a year-over-year increase of 25.1% [4] - Net Product Revenue for Amvuttra in the U.S. was $641.57 million, exceeding the estimated $619.86 million, representing a substantial year-over-year increase of 250.1% [4] - Total product revenues netted $994.72 million, slightly below the estimated $1.01 billion, but reflecting a 120.6% increase compared to the previous year [4] - Net revenues from research collaborators were $40.94 million, significantly lower than the estimated $94.22 million, indicating a year-over-year decline of 61.7% [4] - Royalty revenue was reported at $61.37 million, exceeding the estimated $55.64 million, with a year-over-year increase of 73.4% [4] Stock Performance - Alnylam's shares have returned -12.2% over the past month, contrasting with the Zacks S&P 500 composite's -0.3% change, indicating underperformance relative to the broader market [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the market in the near term [3]